Could one of your patients be interested in a new clinical trial in noncolorectal GI cancer?
Several new clinical studies on non-colorectal gastrointestinal cancers have started recruiting. Maybe one of your patients might benefit from enrolling?Adult patients with this type of liver cancer who have not received any systemic treatment may be interested in an open-label, single-group phase 2 study testing a sequence of proven therapies.
Previously treated, locally advanced unresectable/metastatic gastric, esophageal, pancreatic, or gastroesophageal junction cancer. Participants will be assigned to one of three groups and treated for up to approximately 3 years. The two experimental groups will receive differing doses of AZD0901 by IV infusion. Individuals in the active comparator group will be treated with the investigator's choice of local standard-of-care chemotherapy or targeted therapy.
One group of people in the study will receive an IV infusion of sacituzumab tirumotecan every 2 weeks for up to approximately 4 years. The other individuals will get a physician's choice of standard chemotherapy, such as oral trifluridine-tipiracil, or an IV drug, such as irinotecan, paclitaxel, or docetaxel. Sites in Georgia, Tennessee, Israel, South Korea, and Taiwan started recruiting 450 participants in May 2024. The primary outcome is overall survival, and QoL won't be measured.
Marshall felt that the combination of modified FOLFIRINOX and trabedersen was"unlikely to work" or change the standard of care.
Noncolorectal Gi Cancer Biologic Therapy Biologics Hepatocellular Carcinoma HCC - Hepatocellular Carcinoma Liver Cancer HCC Hepatocellular Cancer Cancer Of The Liver Liver Carcinoma Carcinoma Of The Liver Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Malignant Pancreatic Neoplasm Pancreatic Cancer Cancer Of The Pancreas
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Rice-sized warrior: New LED device uses light to destroy deep cancersNew technology uses light-activated dye to trigger immune response against deep-seated tumors, potentially revolutionizing cancer treatment.
Read more »
Incidence of 17 cancers on the rise in younger generations, major new study saysSome cancers had shown a decline in previous generations.
Read more »
‘Concerning’: New research reveals Gen X, Millennials more susceptible to certain cancersPosition: Reporter
Read more »
Incidence of 17 cancers on the rise in younger generations, major new study saysGen X and Millennials in the U.S. are at greater risk for 17 cancers than were previous generations, a major new study revealed.
Read more »
Incidence of 17 cancers on the rise in younger generations, major new study saysGen X and Millennials in the U.S. are at greater risk for 17 cancers than were previous generations, a major new study revealed.
Read more »
Incidence of 17 cancers on the rise in younger generations, major new study saysGen X and Millennials in the U.S. are at greater risk for 17 cancers than were previous generations, a major new study revealed.
Read more »